Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Cash from Operations came in at 46433000.0 in Q1 2026, down 8.62% YoY from 50811834.56 in Q1 2025, and up 2.61% on a QoQ basis from 47678000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Cash from Operations data on file, last reported at 46433000.0 in Q1 2026.
- Quarterly Cash from Operations fell 8.62% year-over-year to 46433000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 174743000.0 (up 36.01% YoY) and the FY2025 annual result came in at 171059000.0, up 46.47% from the prior year.
- Cash from Operations advanced to 46433000.0 in Q1 2026, from 47678000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 19898000.0 in Q1 2022 to a low of 104531000.0 in Q4 2022.
- A 5-year average of 63810294.12 and a median of 57831000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 441.76% — and 2025, when it surged 69.46%.
- Tracing DNA's Cash from Operations over 5 years: stood at 104531000.0 in 2022, then soared by 44.68% to 57831000.0 in 2023, then gained by 26.62% to 42435000.0 in 2024, then slipped by 12.36% to 47678000.0 in 2025, then increased by 2.61% to 46433000.0 in 2026.
- The last three Cash from Operations figures came in at 46433000.0 (Q1 2026), 47678000.0 (Q4 2025), and 31606000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -44.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.27 Mn |
| Jun 30, 2026 | -44.27 Mn |
| Mar 31, 2026 | -46.43 Mn |
| Mar 31, 2026 | -46.43 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Jun 30, 2025 | -49.03 Mn |
| Jun 30, 2025 | -49.03 Mn |
| Mar 31, 2025 | -42.75 Mn |
| Mar 31, 2025 | -42.75 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Mar 31, 2024 | -89.26 Mn |
| Mar 31, 2024 | -89.26 Mn |